Ryan B. Corcoran, MD, PhD
Mutations in the BRAF gene occur in 10-15% of colorectal cancers and predict poor outcome. Drugs that block the action of mutant BRAF are under active clinical development, and one drug that blocks BRAF was recently approved by the Food and Drug Administration (FDA) for treatment of metastatic melanoma. However, these BRAF inhibitor drugs alone have not been effective in BRAF mutant colorectal cancer patients, suggesting that improved approaches are needed.
Dr. Corcoran’s goal is to develop new treatment strategies for BRAF mutant colorectal cancer. Through a combination of laboratory studies and clinical trials, he plans to identify other key survival signals in BRAF mutant colorectal cancers that can be targeted, in combination with BRAF inhibitors, to improve treatment response in BRAF mutant colorectal cancer patients. Ultimately, he aims to develop novel effective treatments for patients with this lethal subtype of colorectal cancer.
Project Title: "Defining novel targeted therapy combination strategies for BRAF V600 mutant colorectal cancer"
Institution: Massachusetts General Hospital
Sponsor(s) / Mentor(s): Jeffrey A. Engelman, MD, PhD and Keith T. Flaherty, MD
Cancer Type: Colorectal
Research Area: Experimental Therapeutics